AHFS Drug Information®

An Evidence-based Foundation for Safe and Effective Drug Therapy

AHFS Drug Information®
2021st Ed.
2021 © American Society of Health-System Pharmacists®
American Society of Health-System Pharmacists
ISBN-10: 1-58528-654-0 / ISBN-13: 978-1-58528-654-6
ISSN: 8756-6028
Pharmacy/Pharmacology, Drug Information, Neurology, Ophthalmology, Point of Care, Public Health


With this edition, AHFS Drug Information® (AHFS® DI™) marks 63 years of continuous publication as the premier evidence-based drug compendium. The mission of AHFS® DI™ is to provide an evidence-based foundation for safe and effective drug therapy. Widely trusted for its established record in refuting unfounded efficacy claims, its rigorous science-based editorial process, and its independence from the influence of pharmaceutical manufacturers, AHFS® DI™ has remained true to its mission since the first edition was published in 1959. This notable achievement of more than six decades of evidence-based medical publishing has gained AHFS® DI™ the unique distinction of being the longest published federally designated drug compendium issued by a scientific and professional society.

2021 Updates Include:

  • Drug information for COVID-19-related treatments, including use of antiviral agents such as remdesivir and lopinavir/ritonavir, SARS-CoV-2-specific monoclonal antibodies (e.g., bamlanivimab), as well as use of supporting agents such as corticosteroids, immune globulin, nitric oxide, and tocilizumab.
  • Updated information on drugs commonly used for ICU sedation in critically ill patients with COVID-19, including propofol, dexmedetomidine, and midazolam and alternative drugs such as ketamine considered in potential drug shortage situations.
  • Latest oncology therapies for the treatment of cancers associated with activating gene mutations and oncogenic gene fusions.
  • Breakthroughs in oncology approved under the FDA's accelerated approval program.
  • New information on non-oncology off-label uses.

Special Feature: A discussion of recent evidence questioning aspirin’s role in primary prevention of cardiovascular events in most adults, including the American College of Cardiology and American Heart Association’s positions.

This title updates: Monthly

Quotes, Reviews or Testimonials

"This reference is widely used and trusted for its established record in refuting unfounded efficacy claims, its rigorous science-based editorial process, and its independence from the influence of pharmaceutical manufacturers."

-- Jennifer Colon, PharmD, MS, MBA (Temple University School of Pharmacy) - previous edition

"You cannot be a pharmacist without this book. For clinical pharmacists especially it is the standard..."

-- Miriam Klein, Pharm.D. R.Ph. (Woodhull Medical Center) - previous edition

“AHFS Drug Information is by far the most comprehensive and informative drug reference that I use. It offers much more in-depth information and post-marketing [after FDA approval] analysis on drugs.”

-- Jay S. Cohen, M.D., Associate Professor of Family and Preventive Medicine, University of California at San Diego Medical School - previous edition

“There is more in-depth information in AHFS DI, particularly pharmacology and kinetics. At times I especially need the unlabeled uses in AHFS Drug Information to answer questions. Other references don't include as many off-label uses.”

-- Paul Matuschka, Pharm.D., VA Medical Center, Louisville, KY - previous edition


This reference is intended to shape treatment decisions made by practitioners and clinicians and to influence public and private healthcare policies and decisions. It can be used as a valuable and unbiased pharmaceutical reference by clinical students and practitioners.

Table of Contents

Similar Resources